- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03840850
Type 2 Diabetes: Risk Perceptions and Self-management Behaviour
This pilot randomised controlled trial (RCT) aims to assess the feasibility of using a new type of risk communication intervention for people with Type 2 diabetes mellitus (T2DM) in primary care and to evaluate its potential impact on risk perceptions and self-management behaviour.
The study comprises 40 participants with T2DM randomly allocated to usual care supported by the risk communication intervention or usual care only.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes self-management, which includes self-care behaviours such as healthy eating and physical exercise, has become the cornerstone for treating type-2 diabetes mellitus (T2DM). However, although self-management education (SME) is necessary to equip patients with the knowledge, skills and attitudes required to manage their diabetes care, the most effective method to do so is still unclear.
Recent studies have shown that people with T2DM underestimated their risks of developing complications. Although behavioural processes are complex, wrong risk perceptions are a major impediment to the adoption of self-care behaviours and, as a result, an additional risk for the occurrence of adverse outcomes.
Existing risk communication interventions have shown mixed results, with many participants barely understanding the explanations of health professionals about risks and having poor recall of risk information. In this context, there is a need for better risk communication interventions.
Based on the results of recent studies investigating the risk perceptions and risk attitudes of people with T2DM, we have developed a new, tailored risk communication intervention. The objectives of this intervention are:
- To increase the awareness of risks for complications associated with type 2 diabetes.
- To encourage the adoption of recommended self-care behaviours.
The intervention has been developed in collaboration with both health professionals and patients. We have designed a pilot study to assess the feasibility of using the intervention in primary care and to evaluate its potential impact on patients' risk perceptions and self-management behaviour, in order to inform the design of a largest study (RCT to be conducted in the future)
The intervention lasts 5 minutes on average, conducted by the general practitioner (GP) during patients' routine primary care consultation. The study involves 40 participants with T2DM randomly allocated to usual care supported by the risk communication intervention or usual care only.
The research is supported by the National Institute for Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care Oxford at Oxford Health NHS Foundation Trust.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Oxfordshire
-
Oxford, Oxfordshire, United Kingdom, OX1 2NR
- 27 Beaumont Street Surgery Practice
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is willing and able to give informed consent for participation in the study.
- Diagnosed with type-2 diabetes.
Exclusion Criteria:
- Unable to provide informed consent.
- Non-English speaker.
- Not suitable for the study according to GP.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Intervention and usual care
Risk communication intervention and usual care including personalized lifestyle advice
|
The risk communication intervention consists of communicating the impact of being poorly controlled on two types of outcome: (1) absolute 10-year risk of experiencing a cardiovascular event, i.e. heart attack or stroke (10-year CV risk); (2) life expectancy.
These personalized risk estimates are calculated based on the UKPDS outcomes model (version 2), which is a prognostic model of reference in the area of Type 2 diabetes.
|
|
No Intervention: Usual care only
Usual care including personalized lifestyle advice
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility of implementing the intervention in primary care: Binary outcome (feasible / not feasible), as judged by the investigators
Time Frame: 3 months
|
Binary outcome (feasible / not feasible), as judged by the investigators following analysis of study pre-specified outcome measures.
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Recall of personalised risk information
Time Frame: 3 months
|
Recall of personalised risk information is measured immediately and 3 months after the intervention. Type of question used: "The doctor has recently calculated your personalised risk information on his computer. Do you remember these numbers? Binary outcome: information recalled or information not recalled. Recall of information represents a better outcome. Rates of information recall (%) are compared between the two groups. |
3 months
|
|
Intentions to make lifestyle changes
Time Frame: 3 months
|
Intentions to make lifestyle changes are measured immediately before and after the intervention using the validated Determinants of Lifestyle Behaviour Questionnaire (DLBQ).
The DLBQ consists of three parts: intentions to eat healthier, to increase physical activity, and to reduce smoking consumption.
Intentions are assessed by a 5-point Likert scale ranging from 0 (strongly disagree) to 5 (strongly agree).
Each dimension score is assessed individually.
Higher scores represent a better outcome.
|
3 months
|
|
Change in self-management behaviour
Time Frame: 3 months
|
Change in self-management behaviour from baseline to 3 months is measured using the validated Summary of Diabetes Self-Care Activities (SDSCA) questionnaire.
This instrument explores six dimensions of self-management (healthy eating, physical activity, medication adherence, self-monitoring of blood glucose, foot checks and smoking behaviour), using the self-reported frequency of completing recommended activities during the past seven days as an outcome (SDSCA score ranging from 0 to 7 for each dimension).
Each dimension score is assessed individually.
Higher scores represent a better outcome.
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Consent rate
Time Frame: 3 months
|
Rate of eligible subjects consenting to participate in the study (%)
|
3 months
|
|
Acceptability of the intervention
Time Frame: Immediately after the intervention
|
Participants' acceptability of the intervention is measured using adapted questions from the COMRADE (Combined Outcome Measure for Risk communication And treatment Decision-making Effectiveness) scale, which was validated for use in the UK.
This scale consists of 10 questions on a 5-point scale ranging from 0 (strongly disagree) to 5 (strongly agree) and is used immediately after the intervention.
The scores of each question are combined to compute an average score.
Higher average scores represent a better outcome.
|
Immediately after the intervention
|
|
Anxiety due to the intervention
Time Frame: Immediately after the inervention
|
Following Welschen et al. (2012), a question adapted from Claassen et al. (2010) is used to assess how anxious participants are about their personalised risk information (7-point Likert scale ranging from 0 (not anxious at all) to 7 (very much anxious).
Higher scores represent a worse outcome.
|
Immediately after the inervention
|
|
Worry due to the intervention
Time Frame: Immediately after the intervention
|
Following Welschen et al. (2012), a question adapted from Claassen et al. (2010) is used to assess how worried participants are about their personalised risk information (7-point Likert scale ranging from 0 (not worried at all) to 7 (very much worried).
Higher scores represent a worse outcome.
|
Immediately after the intervention
|
|
Retention rate
Time Frame: 3 months
|
Rate of participants who stay enrolled in the study until it ends (%)
|
3 months
|
|
Rate of missing data
Time Frame: 3 months
|
Rate of missing data in participants' self-reported questionnaires (%)
|
3 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 17/NW/0267
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Steno Diabetes Center CopenhagenRecruitingDiabetes | Cognitive Impairment | Type 2 Diabetes | Diabetes Mellitus Type 2 | Cognitive Decline | Type 2 Diabetes Mellitus (T2DM)Denmark
Clinical Trials on Personalized Risk Communication for People with Type 2 Diabetes
-
Pennington Biomedical Research CenterWW International Inc.CompletedOverweight and Obesity | Type2 DiabetesUnited States
-
MajianhuaUnknown
-
Landeskrankenanstalten-BetriebsgesellschaftEuropean CommissionCompletedDiabetes Mellitus Type 2Austria
-
McGill UniversityJuvenile Diabetes Research Foundation; Canadian Institutes of Health Research... and other collaboratorsCompletedType 1 Diabetes Mellitus With HypoglycemiaCanada
-
US Department of Veterans AffairsDuke UniversityCompleted
-
University of Sao PauloUnknown
-
Royal Devon and Exeter NHS Foundation TrustUniversity of ExeterCompletedType 1 Diabetes | Type 1 Diabetes Mellitus Maturity OnsetUnited Kingdom
-
Nemours Children's ClinicCompletedDiabetes Mellitus, Type 2 | Childhood ObesityUnited States
-
Nemours Children's ClinicCompletedDiabetes Mellitus, Type 2 | Childhood ObesityUnited States
-
Medical University of ViennaCharles University, Czech Republic; Rabin Medical Center; Kanuni Sultan Suleyman... and other collaboratorsActive, not recruitingObesity | Diabetes MellitusAustria, Russian Federation, Latvia, Germany, Czechia, Turkey, Greece, Israel